Fresenius SE & Co KGaA
FRE: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€52.00 | Vqljck | Kfnwnqgn |
Fresenius SE Earnings: 2024 Outlook Rises on Solid Biosimilar Launches
Narrow-moat Fresenius SE turned in strong first-quarter results and increased its 2024 outlook on strength in its Kabi injectable therapies segment. At first glance, we do not plan to change our EUR 50 fair value estimate, and shares remain undervalued.